Amy A Irving1, Lori A Plum2, William J Blaser2, Madeline R Ford3, Chao Weng2, Linda Clipson3, Hector F DeLuca2, William F Dove4. 1. McArdle Laboratory for Cancer Research, Department of Oncology, Molecular and Environmental Toxicology Center. 2. Department of Biochemistry, and. 3. McArdle Laboratory for Cancer Research, Department of Oncology. 4. McArdle Laboratory for Cancer Research, Department of Oncology, Laboratory of Genetics, University of Wisconsin-Madison, Madison, WI dove@oncology.wisc.edu.
Abstract
BACKGROUND: Epidemiologic studies in humans have shown associations between greater sunlight exposure, higher serum 25-hydroxycholecalciferol [25(OH)D3] concentrations, and reduced colon cancer risk. However, results from a limited number of vitamin D supplementation trials in humans have not shown a protective effect. OBJECTIVE: We sought to determine whether adding to the diet increasing amounts of either 25(OH)D3, the stable metabolite measured in serum and associated with cancer risk, or cholecalciferol (vitamin D3), the compound commonly used for supplementation in humans, could reduce emergent adenomas (chemoprevention) or decrease the growth of existing adenomas (treatment) in the colons of vitamin D-sufficient rats carrying a truncation mutation of adenomatous polyposis coli (Apc), a model of early intestinal cancer. METHODS: Apc(Pirc/+) rats were supplemented with either vitamin D3 over a range of 4 doses [6-1500 μg/(kg body weight · d)] or with 25(OH)D3 over a range of 6 doses [60-4500 μg/(kg body weight · d)] beginning after weaning. Rats underwent colonoscopy every other week to assess effects on adenoma number and size. At termination (140 d of age), the number of tumors in the small intestine and colon and the size of tumors in the colon were determined, and serum calcium and 25(OH)D3 measurements were obtained. RESULTS: At lower doses (those that did not affect body weight), neither of the vitamin D compounds reduced the number of existing or emergent colonic tumors (P-trend > 0.24). By contrast, supplementation at higher doses (those that caused a suppression in body weight gain) with either 25(OH)D3 or vitamin D3 caused a dose-dependent increase in colonic tumor number in both males and females (P-trend < 0.003). CONCLUSIONS: No evidence for protection against colon tumor development was seen with lower dose supplementation with either cholecalciferol or 25-hydroxycholecalciferol. Thus, the association between sunlight exposure and the incidence of colon cancer may involve factors other than vitamin D concentrations. Alternative hypotheses warrant investigation. Furthermore, this study provides preliminary evidence for the need for caution regarding vitamin D supplementation of humans at higher doses, especially in individuals with sufficient serum 25(OH)D3 concentrations.
BACKGROUND: Epidemiologic studies in humans have shown associations between greater sunlight exposure, higher serum 25-hydroxycholecalciferol [25(OH)D3] concentrations, and reduced colon cancer risk. However, results from a limited number of vitamin D supplementation trials in humans have not shown a protective effect. OBJECTIVE: We sought to determine whether adding to the diet increasing amounts of either 25(OH)D3, the stable metabolite measured in serum and associated with cancer risk, or cholecalciferol (vitamin D3), the compound commonly used for supplementation in humans, could reduce emergent adenomas (chemoprevention) or decrease the growth of existing adenomas (treatment) in the colons of vitamin D-sufficient rats carrying a truncation mutation of adenomatous polyposis coli (Apc), a model of early intestinal cancer. METHODS:Apc(Pirc/+) rats were supplemented with either vitamin D3 over a range of 4 doses [6-1500 μg/(kg body weight · d)] or with 25(OH)D3 over a range of 6 doses [60-4500 μg/(kg body weight · d)] beginning after weaning. Rats underwent colonoscopy every other week to assess effects on adenoma number and size. At termination (140 d of age), the number of tumors in the small intestine and colon and the size of tumors in the colon were determined, and serum calcium and 25(OH)D3 measurements were obtained. RESULTS: At lower doses (those that did not affect body weight), neither of the vitamin D compounds reduced the number of existing or emergent colonic tumors (P-trend > 0.24). By contrast, supplementation at higher doses (those that caused a suppression in body weight gain) with either 25(OH)D3 or vitamin D3 caused a dose-dependent increase in colonic tumor number in both males and females (P-trend < 0.003). CONCLUSIONS: No evidence for protection against colon tumor development was seen with lower dose supplementation with either cholecalciferol or 25-hydroxycholecalciferol. Thus, the association between sunlight exposure and the incidence of colon cancer may involve factors other than vitamin D concentrations. Alternative hypotheses warrant investigation. Furthermore, this study provides preliminary evidence for the need for caution regarding vitamin D supplementation of humans at higher doses, especially in individuals with sufficient serum 25(OH)D3 concentrations.
Authors: James M Amos-Landgraf; Jarom Heijmans; Mattheus C B Wielenga; Elisa Dunkin; Kathy J Krentz; Linda Clipson; Antwan G Ederveen; Patrick G Groothuis; Sietse Mosselman; Vanesa Muncan; Daniel W Hommes; Alexandra Shedlovsky; William F Dove; Gijs R van den Brink Journal: Proc Natl Acad Sci U S A Date: 2014-11-03 Impact factor: 11.205
Authors: Amy A Irving; Richard B Halberg; Dawn M Albrecht; Lori A Plum; Kathleen J Krentz; Linda Clipson; Norman Drinkwater; James M Amos-Landgraf; William F Dove; Hector F DeLuca Journal: Arch Biochem Biophys Date: 2011-09-01 Impact factor: 4.013
Authors: Kana Wu; Diane Feskanich; Charles S Fuchs; Walter C Willett; Bruce W Hollis; Edward L Giovannucci Journal: J Natl Cancer Inst Date: 2007-07-10 Impact factor: 13.506
Authors: Amy A Irving; Kazuto Yoshimi; Marcia L Hart; Taybor Parker; Linda Clipson; Madeline R Ford; Takashi Kuramoto; William F Dove; James M Amos-Landgraf Journal: Dis Model Mech Date: 2014-10-02 Impact factor: 5.758
Authors: Yazhou He; Maria Timofeeva; Susan M Farrington; Peter Vaughan-Shaw; Victoria Svinti; Marion Walker; Lina Zgaga; Xiangrui Meng; Xue Li; Athina Spiliopoulou; Xia Jiang; Elina Hyppönen; Peter Kraft; Douglas P Kiel; Caroline Hayward; Archie Campbell; David Porteous; Katarina Vucic; Iva Kirac; Masa Filipovic; Sarah E Harris; Ian J Deary; Richard Houlston; Ian P Tomlinson; Harry Campbell; Evropi Theodoratou; Malcolm G Dunlop Journal: BMC Med Date: 2018-08-14 Impact factor: 8.775